Candriam Luxembourg S.C.A. boosted its position in shares of Genomic Health, Inc. (NASDAQ:GHDX) by 4.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 99,000 shares of the medical research company’s stock after buying an additional 4,000 shares during the period. Candriam Luxembourg S.C.A. owned approximately 0.29% of Genomic Health worth $3,223,000 as of its most recent SEC filing.
A number of other large investors have also recently modified their holdings of the stock. Dubuque Bank & Trust Co. purchased a new stake in shares of Genomic Health during the first quarter worth approximately $142,000. Legal & General Group Plc raised its stake in shares of Genomic Health by 48.7% in the first quarter. Legal & General Group Plc now owns 6,222 shares of the medical research company’s stock worth $196,000 after buying an additional 2,038 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Genomic Health during the first quarter worth approximately $218,000. Stonebridge Capital Management Inc. purchased a new stake in shares of Genomic Health during the first quarter worth approximately $259,000. Finally, Envestnet Asset Management Inc. raised its stake in shares of Genomic Health by 13.6% in the first quarter. Envestnet Asset Management Inc. now owns 8,282 shares of the medical research company’s stock worth $259,000 after buying an additional 993 shares in the last quarter. Hedge funds and other institutional investors own 88.54% of the company’s stock.
Genomic Health, Inc. (GHDX) traded down 1.43% during midday trading on Friday, reaching $29.59. The company’s stock had a trading volume of 91,229 shares. The stock’s 50 day moving average is $31.85 and its 200 day moving average is $31.25. The stock’s market cap is $1.03 billion. Genomic Health, Inc. has a 12-month low of $25.66 and a 12-month high of $33.97.
Genomic Health (NASDAQ:GHDX) last released its quarterly earnings results on Tuesday, August 1st. The medical research company reported ($0.08) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.06) by $0.02. Genomic Health had a negative return on equity of 4.33% and a negative net margin of 1.50%. The company had revenue of $85.50 million during the quarter, compared to analyst estimates of $86.08 million. During the same period last year, the firm earned ($0.18) earnings per share. The business’s revenue was up 4.3% compared to the same quarter last year. Analysts anticipate that Genomic Health, Inc. will post ($0.01) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This story was first reported by BNB Daily and is the property of of BNB Daily. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.baseball-news-blog.com/2017/08/19/genomic-health-inc-ghdx-stake-raised-by-candriam-luxembourg-s-c-a-updated.html.
GHDX has been the topic of a number of recent research reports. Canaccord Genuity dropped their target price on Genomic Health from $36.00 to $35.00 and set a “buy” rating on the stock in a research report on Tuesday. Piper Jaffray Companies reiterated a “hold” rating and issued a $31.00 target price on shares of Genomic Health in a research report on Thursday, August 3rd. Jefferies Group LLC restated a “hold” rating and issued a $33.00 price objective on shares of Genomic Health in a research report on Monday, June 12th. Raymond James Financial, Inc. restated a “market perform” rating on shares of Genomic Health in a research report on Wednesday, May 3rd. They noted that the move was a valuation call. Finally, BidaskClub lowered Genomic Health from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $32.00.
In related news, insider Phillip G. Febbo sold 3,174 shares of the company’s stock in a transaction on Wednesday, July 19th. The stock was sold at an average price of $33.57, for a total value of $106,551.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Steven Shak sold 5,000 shares of the company’s stock in a transaction on Tuesday, May 23rd. The shares were sold at an average price of $29.40, for a total value of $147,000.00. The disclosure for this sale can be found here. Insiders sold 47,642 shares of company stock valued at $1,503,731 over the last quarter. Insiders own 46.20% of the company’s stock.
About Genomic Health
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.